NCT03066193View on ClinicalTrials.gov

Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Tourette Syndrome
Interventions
DRUG

Dronabinol and Palmitoylethanolamide

Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.

Trial Locations (1)

06520

Yale Child Study Center, New Haven

Sponsors

Collaborators (1)

SciSparc
All Listed Sponsors
collaborator

SciSparc

INDUSTRY

lead

Yale University

OTHER

NCT03066193 - Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome | Biotech Hunter | Biotech Hunter